Fundraising Fox

Annexon

So. San Francisco, US · Founded 2011 · 114 employees on LinkedIn · 4 known investors

Find your way into Annexon

118 people in our graph share verified history with the Annexon team — schools, employers, funds. One of them is your warm intro.

Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases. Its therapies aim to block complement-driven damage affecting the body, brain, and eye.

Founders & leadership

Annexon was founded in 2011 by Ben Barres and Douglas Love.

BB
Ben BarresScientific Co-Founder
DLDouglas Love
Douglas LoveinCo-founder · President & CEODouglas Love is Founder and CEO of Annexon Biosciences, a biopharmaceutical company developing complement inhibitors targeting C1q for autoimmune, neurodegenerative, and ophthalmic diseases.
ML
Mark L SmithExecutive
CM
Campbell MurrayNamed on SEC filing
TW
Thomas WiggansNamed on SEC filing
RSRicky Sun
Ricky SunNamed on SEC filingPartner at Bain Capital Life Sciences
TY
Ted YednockNamed on SEC filing
WY
William YoungNamed on SEC filing

Board

EC
Emmett CunninghamBoard director
MS
Muneer SatterBoard director
CG
Carol GallagherBoard director

Investors · 4

Reported raises · per SEC filings

Form D private placements

$277.5M disclosed across 3 rounds · 2018–2022

$130.5MraisedJul 2022 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William D. WaddillDirector
  • Thomas G. WiggansDirector
  • Muneer A. SatterDirector
  • Michael OverdorfExecutive Officer
  • Larry C. Mattheakis, Ph.DExecutive Officer
  • Douglas LoveExecutive Officer, Director
  • Jennifer LewExecutive Officer
  • Bettina M. Cockroft, M.D.Director
  • William H. Carson, M.D.Director
  • Jung E. ChoiDirector
Offering amount
$130.5M
Amount sold
$130.5M
Sales commissions
$6.7M
Placement agents
Jefferies LLC, Cowen and Company, LLC
First sale
Jul 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$102MraisedJul 2020 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ted YednockExecutive Officer
  • Jung E. ChoiDirector
  • William D. YoungDirector
  • Emmett CunninghamDirector
  • Thomas G. WiggansDirector
  • Carol GallagherDirector
  • Muneer A. SatterDirector
  • Campbell MurrayDirector
  • Sanjay KeswaniExecutive Officer
  • Jennifer LewExecutive Officer
  • Douglas LoveExecutive Officer, Director
  • Ricky SunDirector
Offering amount
$102M
Amount sold
$102M
First sale
Jun 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$45MraisedDec 2018 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Campbell MurrayDirector
  • Douglas LoveExecutive Officer, Director
  • Thomas WiggansDirector
  • Emmett CunninghamDirector
  • Ricky SunDirector
  • Muneer SatterDirector
  • Carol GallagherDirector
  • Ted YednockExecutive Officer
  • William YoungDirector
  • Mark L SmithExecutive Officer
Offering amount
$85M
Amount sold
$45M
First sale
Dec 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Annexon do?
Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases. Its therapies aim to block complement-driven damage affecting the body, brain, and eye.
Who founded Annexon?
Annexon was founded by Ben Barres, Douglas Love in 2011.
Who are Annexon's investors?
Annexon's investors include Bain Capital Life Sciences, Correlation Ventures, New Enterprise Associates (NEA), Clarus.
How much funding has Annexon raised?
Annexon has disclosed $277.5M raised across 3 rounds.
Where is Annexon headquartered?
Annexon is headquartered in So. San Francisco, US.